As the drug industry and its supporters continue to push back against further implementation of government price controls, saying the controls will hinder investment in future treatments and cures, a report from a nonpartisan special interest watchdog group found the industry spends more on stock buybacks, marketing and other priorities than research and development. Accountable.US Executive Director Tony Carrk wrote last month in a Pittsburgh Post-Gazette op-ed that drug companies could shift their priorities to avoid having to make...